

Jorg Dietrich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1576715/publications.pdf>

Version: 2024-02-01

129
papers

4,077
citations

136950

32
h-index

138484

58
g-index

130
all docs

130
docs citations

130
times ranked

6103
citing authors

#	ARTICLE	IF	CITATIONS
1	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1590-1599.	10.7	535
2	Clinical Patterns and Biological Correlates of Cognitive Dysfunction Associated with Cancer Therapy. <i>Oncologist</i> , 2008, 13, 1285-1295.	3.7	297
3	Corticosteroids in brain cancer patients: benefits and pitfalls. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 233-242.	3.1	263
4	Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. <i>Blood</i> , 2019, 133, 2212-2221.	1.4	207
5	Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. <i>Blood</i> , 2019, 134, 860-866.	1.4	178
6	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
7	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. <i>Clinical Cancer Research</i> , 2016, 22, 1632-1641.	7.0	127
8	Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. <i>Journal of Neurosurgery</i> , 2019, 130, 804-811.	1.6	114
9	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. <i>Nature Communications</i> , 2018, 9, 1474.	12.8	106
10	Neural correlates of chemotherapy-related cognitive impairment. <i>Cortex</i> , 2014, 54, 33-50.	2.4	104
11	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
12	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020, 26, 1280-1284.	30.7	83
13	MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. <i>Blood Advances</i> , 2019, 3, 375-383.	5.2	77
14	Standard chemoradiation for glioblastoma results in progressive brain volume loss. <i>Neurology</i> , 2015, 85, 683-691.	1.1	70
15	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 603-610.	2.9	69
16	Pharmacologic management of cognitive impairment induced by cancer therapy. <i>Lancet Oncology, The</i> , 2019, 20, e92-e102.	10.7	68
17	Role of ketogenic metabolic therapy in malignant glioma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 41-58.	4.4	67
18	Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 133-145.	3.8	65

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. <i>Blood</i> , 2022, 139, 2306-2315.	1.4	62
20	Strategies to Prevent or Remediate Cancer and Treatment-Related Aging. <i>Journal of the National Cancer Institute</i> , 2021, 113, 112-122.	6.3	57
21	Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1549-1557.	4.1	50
22	Evolution of cerebral microbleeds after cranial irradiation in medulloblastoma patients. <i>Neurology</i> , 2017, 88, 789-796.	1.1	49
23	Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 206-212.	7.0	48
24	Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 393-404.	4.3	47
25	Emerging antiangiogenic treatments for gliomas – efficacy and safety issues. <i>Current Opinion in Neurology</i> , 2008, 21, 736-744.	3.6	46
26	Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2042-2042.	1.6	44
27	Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. <i>Journal of Neuro-Oncology</i> , 2016, 127, 505-514.	2.9	42
28	Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. <i>Cancer</i> , 2019, 125, 3692-3698.	4.1	42
29	Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2019, 142, 69-77.	2.9	39
30	EEG findings in CAR T-cell therapy-related encephalopathy. <i>Neurology</i> , 2018, 91, 227-229.	1.1	37
31	Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. <i>Neuro-Oncology</i> , 2019, 21, 1118-1130.	1.2	37
32	Role of Endogenous Neural Stem Cells in Neurological Disease and Brain Repair. , 2006, 557, 191-220.		37
33	Chemotherapy Associated Central Nervous System Damage. <i>Advances in Experimental Medicine and Biology</i> , 2010, 678, 77-85.	1.6	36
34	Bone marrow drives central nervous system regeneration after radiation injury. <i>Journal of Clinical Investigation</i> , 2017, 128, 281-293.	8.2	36
35	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. <i>Nature Communications</i> , 2021, 12, 5954.	12.8	35
36	Glioma stem cell signaling: therapeutic opportunities and challenges. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 709-722.	2.4	34

#	ARTICLE	IF	CITATIONS
37	Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).. Journal of Clinical Oncology, 2019, 37, 2032-2032.	1.6	33
38	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nature Communications, 2022, 13, 1325.	12.8	31
39	Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. Cancer Medicine, 2020, 9, 3-11.	2.8	28
40	Bone marrow response as a potential biomarker of outcomes in glioblastoma patients. Journal of Neurosurgery, 2017, 127, 132-138.	1.6	25
41	Primary dural lymphomas: Clinical presentation, management, and outcome. Cancer, 2020, 126, 2811-2820.	4.1	24
42	Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Medicine, 2019, 8, 5988-5994.	2.8	23
43	Defining Treatment-Related Adverse Effects in Patients with Glioma: Distinctive Features of Pseudoprogression and Treatment-Induced Necrosis. Oncologist, 2020, 25, e1221-e1232.	3.7	23
44	Cognitive Performance and Psychological Distress in Breast Cancer Patients at Disease Onset. Frontiers in Psychology, 2019, 10, 2584.	2.1	20
45	Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. Clinical Cancer Research, 2022, 28, 2567-2578.	7.0	20
46	Chimeric Antigen Receptor T Cells for Glioblastoma. Neurology, 2021, 97, 218-230.	1.1	19
47	Neuroimaging of Brain Tumors: Pseudoprogression, Pseudoresponse, and Delayed Effects of Chemotherapy and Radiation. Seminars in Neurology, 2017, 37, 589-596.	1.4	19
48	Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas. Radiology, 2020, 294, 589-597.	7.3	18
49	Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity. BMJ Neurology Open, 2020, 2, e000054.	1.6	18
50	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. Npj Precision Oncology, 2017, 1, .	5.4	16
51	Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis. Journal of Neuro-Oncology, 2020, 149, 153-159.	2.9	16
52	Perceptions of prognosis and goal of treatment in patients with malignant gliomas and their caregivers. Neuro-Oncology Practice, 2020, 7, 490-497.	1.6	16
53	Ipilimumab: an investigational immunotherapy for glioblastoma. Expert Opinion on Investigational Drugs, 2020, 29, 1187-1193.	4.1	16
54	Imaging of Cancer Therapy-Induced Central Nervous System Toxicity. Neurologic Clinics, 2014, 32, 147-157.	1.8	15

#	ARTICLE	IF	CITATIONS
55	Engraftment of enteric neural progenitor cells into the injured adult brain. BMC Neuroscience, 2016, 17, 5.	1.9	13
56	A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood, 2021, 138, 382-386.	1.4	13
57	Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma. Radiology, 2022, 302, 410-418.	7.3	13
58	Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss. Neuro-Oncology, 2018, 20, 289-291.	1.2	12
59	An integrated RF-receive/B0-shim array coil boosts performance of whole-brain MR spectroscopic imaging at 7ÅT. Scientific Reports, 2020, 10, 15029.	3.3	12
60	Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II. Scientific Reports, 2020, 10, 19758.	3.3	11
61	Assessment and Management of Cognitive Symptoms in Patients With Brain Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e90-e99.	3.8	11
62	Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. Neuro-Oncology Practice, 2018, 5, 64-68.	1.6	10
63	Clinical Presentation and Management of SMART Syndrome. Neurology, 2021, 97, 118-120.	1.1	10
64	Central nervous system injury from novel cancer immunotherapies. Current Opinion in Neurology, 2020, 33, 723-735.	3.6	9
65	Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial. Oncologist, 2020, 25, 747-e1273.	3.7	9
66	Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neuro-Oncology Advances, 2020, 2, vdaa157.	0.7	8
67	Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa031.	0.7	8
68	Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES). Journal of Cancer Research and Clinical Oncology, 2019, 145, 1917-1918.	2.5	7
69	Effect of Cancer Treatment on Neural Stem and Progenitor Cells. Cancer Treatment and Research, 2009, 150, 81-95.	0.5	6
70	ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB,) Tj ETQq0 0 0 rgBT /Overl Neuro-Oncology, 2018, 20, vi10-vi10.	1.2	6
71	ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM. Neuro-Oncology, 2018, 20, vi13-vi14.	1.2	6
72	Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults. Journal of Neuro-Oncology, 2020, 150, 165-213.	2.9	6

#	ARTICLE	IF	CITATIONS
73	Assessment and management of cognitive changes in patients with cancer. <i>Cancer</i> , 2019, 125, 1958-1962.	4.1	5
74	MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab060.	0.7	5
75	Fatal neurotoxicity after chimeric antigen receptor T-cell therapy: An unexpected case of fludarabine-associated progressive leukoencephalopathy. <i>European Journal of Cancer</i> , 2021, 144, 178-181.	2.8	5
76	Reliability and validity of a novel cognitive self-assessment tool for patients with cancer. <i>Neuro-Oncology Practice</i> , 2021, 8, 691-698.	1.6	5
77	Magnetic Resonance Imaging Observations in Primary Central Nervous System Lymphoma. <i>JAMA Neurology</i> , 2014, 71, 918.	9.0	4
78	Remote acute demyelination after focal proton radiation therapy for optic nerve meningioma. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1367-1369.	1.5	4
79	Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2080-TPS2080.	1.6	4
80	Challenges in research on the neural basis of "chemobrain". <i>Translational Neuroscience</i> , 2014, 5, .	1.4	3
81	Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. <i>Oncologist</i> , 2019, 24, 402-413.	3.7	3
82	Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. <i>Neuro-Oncology Practice</i> , 2021, 8, 259-265.	1.6	3
83	Intracranial Foreign Body Granuloma Mimicking Brain Tumor Recurrence: A Case Series. <i>Oncologist</i> , 2021, 26, e893-e897.	3.7	3
84	Intratumoral drug distribution of adavosertib in patients with glioblastoma: Interim results of phase I study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2568-2568.	1.6	3
85	Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma. <i>Blood</i> , 2021, 138, 258-258.	1.4	3
86	Factors associated with psychological distress in caregivers of patients with malignant gliomas. <i>Supportive Care in Cancer</i> , 2022, 30, 5811-5820.	2.2	3
87	Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2030-2030.	1.6	3
88	Perspectives on investigational drugs and immunotherapies for glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1007-1009.	4.1	2
89	The best matrix for the brain: advances in secondary CNS lymphoma. <i>Lancet Haematology</i> , 2021, 8, e96-e97.	4.6	2
90	Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS2104-TPS2104.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).. Journal of Clinical Oncology, 2015, 33, TPS2077-TPS2077.	1.6	2
92	Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.. Journal of Clinical Oncology, 2017, 35, 2005-2005.	1.6	2
93	Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2032-2032.	1.6	2
94	Central Nervous System Complications Among Oncology Patients. Hematology/Oncology Clinics of North America, 2022, 36, 217-236.	2.2	2
95	Improving Dâ€²â€²-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RFâ€²receive/B₀</sub>â€²shim array coils at 3â€²%T. NMR in Biomedicine, 2022, 35, 2.e4621.	2.8	2
96	In Vivo Absolute Metabolite Quantification Using a Multiplexed <sc>ERETICâ€²RX</sc> Array Coil for Wholeâ€²Brain <sc>MR</sc> Spectroscopic Imaging. Journal of Magnetic Resonance Imaging, 2022, 56, 121-133.	3.4	2
97	Deep Learning Super-resolution MR Spectroscopic Imaging of Brain Metabolism and Mutant IDH Glioma. Neuro-Oncology Advances, 0, , .	0.7	2
98	A controlled comparison of cerebral volume loss after brain irradiation with proton versus photon radiotherapy.. Journal of Clinical Oncology, 2022, 40, 2017-2017.	1.6	2
99	Metastatic primary peritoneal carcinoma presenting as tension hydrothorax. Lancet Oncology, The, 2006, 7, 784.	10.7	1
100	A 20-Year-Old Man With Back Pain and Lower Extremity Weakness. JAMA Neurology, 2015, 72, 363.	9.0	1
101	A 34â€²Yearâ€²Old Male with An Intracranial Mass. Brain Pathology, 2016, 26, 289-290.	4.1	1
102	NCOG-04. EFFECTS OF PROTON RADIATION ON BRAIN STRUCTURE AND FUNCTION IN LOW GRADE GLIOMA. Neuro-Oncology, 2018, 20, vi173-vi173.	1.2	1
103	NCMP-22. TREATMENT-RELATED ADVERSE EFFECTS IN PATIENTS WITH MALIGNANT GLIOMA: ESTABLISHMENT OF KEY FEATURES FOR PSEUDOPROGRESSION AND TREATMENT-INDUCED NECROSIS.. Neuro-Oncology, 2018, 20, vi198-vi198.	1.2	1
104	NCMP-17. EVOLUTION OF CEREBRAL MICROBLEEDS AFTER PROTON IRRADIATION IN LOW-GRADE GLIOMA PATIENTS. Neuro-Oncology, 2018, 20, vi197-vi197.	1.2	1
105	Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: Final results.. Journal of Clinical Oncology, 2014, 32, 2053-2053.	1.6	1
106	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2015, 33, 2025-2025.	1.6	1
107	Subventricular zone involvement is associated with worse outcome in glioma WHO grade 2 depending on molecular markers. Scientific Reports, 2021, 11, 20045.	3.3	1
108	MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas.. Journal of Clinical Oncology, 2018, 36, e14041-e14041.	1.6	1

#	ARTICLE	IF	CITATIONS
109	BIOM-15. SUBVENTRICULAR ZONE INVOLVEMENT IS ASSOCIATED WITH WORSE OUTCOME IN GLIOMA WHO GRADE II INDEPENDENT OF MOLECULAR MARKERS. <i>Neuro-Oncology</i> , 2020, 22, ii4-ii5.	1.2	1
110	Antiepileptic drug therapy in brain tumor patients: a complex relationship. <i>Neuro-Oncology Practice</i> , 2022, 9, 83-84.	1.6	1
111	MPTH-17CLINICAL AND MOLECULAR CHARACTERIZATION OF LONG-TERM GLIOBLASTOMA SURVIVORS. <i>Neuro-Oncology</i> , 2015, 17, v141.4-v142.	1.2	0
112	NTCT-03CEREBRAL MICROBLEEDS AFTER WHOLE BRAIN RADIATION THERAPY IN MEDULLOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2015, 17, v172.3-v172.	1.2	0
113	HOUT-15. CIRCULATING BLOOD CELL COUNTS AS POTENTIAL BIOMARKERS OF OUTCOMES IN RECURRENT GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB. <i>Neuro-Oncology</i> , 2018, 20, vi116-vi116.	1.2	0
114	NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE. <i>Neuro-Oncology</i> , 2018, 20, vi191-vi191.	1.2	0
115	EXTH-39. BENCH TO BEDSIDE NEURO-ONCOLOGY: ADVOCATING FOR A CLINICALLY RELEVANT STRATEGY. <i>Neuro-Oncology</i> , 2019, 21, vi90-vi90.	1.2	0
116	QOLP-38. PATIENT REPORTED OUTCOMES IN GLIOMA: THE ROLE OF IDH MUTATION ON QUALITY OF LIFE AND MOOD. <i>Neuro-Oncology</i> , 2019, 21, vi206-vi206.	1.2	0
117	MRI findings in trigeminal neuropathy: bilateral Meckel's cave lesions. <i>Acta Neurologica Belgica</i> , 2020, 120, 171-173.	1.1	0
118	BIMG-22. DEEP LEARNING SUPER-RESOLUTION MR SPECTROSCOPIC IMAGING TO MAP TUMOR METABOLISM IN MUTANT IDH GLIOMA PATIENTS. <i>Neuro-Oncology Advances</i> , 2021, 3, i5-i6.	0.7	0
119	Myelopathies from Neoplasms. <i>Seminars in Neurology</i> , 2021, 41, 291-302.	1.4	0
120	MRI changes in patients with newly diagnosed glioblastoma treated as part of a phase II trial with bavituximab, radiation, and temozolomide.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2546-2546.	1.6	0
121	NCOG-48. LONGITUDINAL ASSESSMENT OF SUBJECTIVE COGNITIVE FUNCTION IN A BRAIN TUMOR SAMPLE: IMPROVED CORRESPONDENCE WITH NEUROPSYCHOLOGICAL PERFORMANCE OVER TIME. <i>Neuro-Oncology</i> , 2021, 23, vi162-vi162.	1.2	0
122	BIOM-09. MYO-INOSITOL LEVELS ON MR SPECTROSCOPY CAN PREDICT FAILURE OF ANTI-ANGIOGENIC TREATMENT IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi11-vi12.	1.2	0
123	CTIM-30. PHASE II TRIAL OF PEMBROLIZUMAB IN RECURRENT AND RESIDUAL HIGH-GRADE MENINGIOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi57-vi57.	1.2	0
124	TAMI-29. MR SPECTROSCOPY MEASURES OF LAC/NAA AND NAA/CHO DIFFERENTIATE SURVIVORSHIP IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH ANTI-ANGIOGENIC THERAPY. <i>Neuro-Oncology</i> , 2021, 23, vi204-vi204.	1.2	0
125	NCOG-20. LONGITUDINAL ASSESSMENT OF SUBJECTIVE COGNITIVE FUNCTION IN ADULTS WITH LOW GRADE GLIOMA TREATED WITH PROTON RADIATION THERAPY. <i>Neuro-Oncology</i> , 2021, 23, vi156-vi156.	1.2	0
126	NCOG-70. RELIABILITY AND VALIDITY OF A NEW SELF-REPORT INDEX OF COGNITIVE CONCERNS IN BRAIN TUMOR PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii145-ii145.	1.2	0

#	ARTICLE	IF	CITATIONS
127	BIOM-54. A RAPID GENOTYPING PANEL FOR SENSITIVE AND SPECIFIC SEGREGATION OF CNS PATHOLOGIES. Neuro-Oncology, 2020, 22, ii13-ii13.	1.2	0
128	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. Neuro-Oncology, 2021, 23, vi49-vi49.	1.2	0
129	Magnetic Resonance Spectroscopic Imaging for Detecting Metabolic Changes in Glioblastoma After Anti-angiogenic Therapy-A Systematic Literature Review. Neuro-Oncology Advances, 0, , .	0.7	0